^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    MIR383 (MicroRNA 383)

    i
    Other names: MIR383, MicroRNA 383, Hsa-MiR-383-5p, Hsa-Mir-383, MIRN383, Hsa-Mir-383-V1_pre, Hsa-Mir-383-V2_pre, Hsa-MiR-383-3p, MIMAT0000738, MIMAT0026485, MI0000791, Mir-383, RF00715
    Associations

    News

    Trials
    3ms
    Molecular mechanism of LncRNA MALAT1 in regulating hepatocellular carcinoma progression via the miR-383-5p/PRKAG1 axis and its role in the tumor immune microenvironment. (PubMed, Front Oncol)
    This study elucidates the oncogenic role of the MALAT1/miR-383-5p/PRKAG1 axis in HCC, demonstrating that PRKAG1 promotes tumor progression by regulating cell proliferation, the immune microenvironment, and key signaling pathways. These findings provide potential novel targets for HCC prognosis assessment and targeted therapy.
    Journal
    |
    CD4 (CD4 Molecule) • MALAT1 (Metastasis associated lung adenocarcinoma transcript 1) • PRKAG1 (Protein Kinase AMP-Activated Non-Catalytic Subunit Gamma 1) • AMPK (Protein Kinase AMP-Activated Catalytic Subunit Alpha 1) • MIR383 (MicroRNA 383)
    3ms
    Upregulation of Hsa_circ_0077007 Expression is Used for Prognosis and Targeted Therapy of Colorectal Cancer. (PubMed, Biochem Genet)
    High expression of hsa_circ_0077007 is indicative of shorter survival rates among CRC patients. The hsa_circ_0077007 has been demonstrated to enhance cellular proliferation, invasion, and migration, while concurrently inhibiting apoptosis.
    Journal
    |
    MIR383 (MicroRNA 383)
    5ms
    Synergistic Effect of miR-383 and Cisplatin on Inhibition of Growth, Proliferation, and Migration of Lung Cancer Cells. (PubMed, Arch Iran Med)
    The findings indicate that the combination treatment of miR-383 and cisplatin suppressed cell proliferation, migration and colony formation while enhancing the sensitivity of A549 cells to chemotherapy compared to monotherapy. These results suggest that miR-383 combination therapy warrants further investigation as a potential strategy for LC treatment.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • MMP2 (Matrix metallopeptidase 2) • CASP3 (Caspase 3) • MIR383 (MicroRNA 383)
    |
    cisplatin
    6ms
    New microRNA-based therapies reveal common targets in paediatric medulloblastoma and adult glioblastoma. (PubMed, Sci Rep)
    The role of both miRNAs on their target genes was validated through in vitro functional assays. Our study uncovers the potential role of miR-206/CORO1C and miR-383/SV2B axes as innovative therapeutic targets for combating aggressive paediatric and adult brain malignancies.
    Journal
    |
    MIR206 (MicroRNA 206) • CORO1C (Coronin 1C) • MIR383 (MicroRNA 383)
    9ms
    Identification of Deregulated miRNAs and mRNAs Involved in Tumorigenesis and Detection of Glioblastoma Patients Applying Next-Generation RNA Sequencing. (PubMed, Pharmaceuticals (Basel))
    Based on the PPI network, a functional enrichment analysis of the target proteins was also carried out. (4) We identified an miRNA panel and several deregulated mRNAs that could play an important role in tumor development and distinguish GBM patients from healthy controls with high sensitivity and specificity using total RNA isolated from tissue samples.
    Journal
    |
    MIR21 (MicroRNA 21) • AURKB (Aurora Kinase B) • MIR490 (MicroRNA 490) • MYBL2 (MYB Proto-Oncogene Like 2) • CDC45 (Cell Division Cycle 45) • E2F2 (E2F Transcription Factor 2) • FABP6 (Fatty Acid Binding Protein 6) • HOXC10 (Homeobox C10) • MIR10B (MicroRNA 10b) • MIR383 (MicroRNA 383)
    10ms
    Unveiling the transcriptional pattern of Epithelial ovarian carcinoma-related microRNAs-mRNAs network after mouse exposure to 2,3,7,8-Tetrachlorodibenzo-p-dioxin. (PubMed, Reprod Toxicol)
    Using TR-qPCR, we evaluated the downstream impact of TCDD-dysregulated miRNAs on their target genes. Our results indicate that TCDD-induced upregulation of oncogenic miRNAs negatively regulates target genes associated with EOC, while downregulation of cancer-suppressor miRNAs positively regulates genes linked to EOC.
    Preclinical • Journal
    |
    MIR200B (MicroRNA 200b) • MIR21 (MicroRNA 21) • MIR34A (MicroRNA 34a-5p) • MIR429 (MicroRNA 429) • MIR200A (MicroRNA 200a) • MIR27A (MicroRNA 27a) • MIR141 (MicroRNA 141) • MIR182 (MicroRNA 182) • MIR199A (MicroRNA 199a) • MIR210 (MicroRNA 210) • MIR23b (MicroRNA 23b) • MIR99A (MicroRNA 99a) • MIR140 (MicroRNA 140) • MIR15A (MicroRNA 15a) • MIR183 (MicroRNA 183) • MIR19A (MicroRNA 19a) • MIR30A (MicroRNA 30a) • MIR383 (MicroRNA 383)
    11ms
    HIF-1α and VEGF Immunophenotypes as Potential Biomarkers in the Prognosis and Evaluation of Treatment Efficacy of Atherosclerosis: A Systematic Review of the Literature. (PubMed, Front Biosci (Landmark Ed))
    We present an overview of HIF-1α/VEGF expression in chronic inflammatory-related atherosclerosis disease. Exploring pathogenetic mechanisms and therapeutic options, we included several studies using variable methods to evaluate HIF-1α/VEGF immunophenotypes with controversial and innovative results. Data limitations may include the use of different survival methods. Our data support HIF-1α/VEGF immunophenotypes as potential biomarkers of atherosclerosis prognosis and treatment efficacy.
    Review
    |
    IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • IL18 (Interleukin 18) • STAT6 (Signal transducer and activator of transcription 6) • IL1B (Interleukin 1, beta) • MIR497 (MicroRNA 497) • MIR383 (MicroRNA 383)
    11ms
    Eugenol inhibits NEAT1 as a ceRNA in pre-cancerous breast lesions. (PubMed, Heliyon)
    EU suppressed MCF-10AT cell growth, decreasing the NEAT1, VEGF-A, and MMP-9 levels and increasing miR-383-5p and miR-9-5p expressions in vitro and in vivo. In summary, the EU reduced the VEGF-A and MMP-9 expressions via NEAT1-mediated miR-383-5p and miR-9-5p against PBL, indicating that the EU may be a promising external drug to act against PBL.
    Journal
    |
    NEAT1 (Nuclear Paraspeckle Assembly Transcript 1) • MMP9 (Matrix metallopeptidase 9) • MIR383 (MicroRNA 383)
    12ms
    Expression and Clinical Significance of miR-383-5p in Multiple Myeloma Cells (PubMed, Zhongguo Shi Yan Xue Ye Xue Za Zhi)
    The expression of miR-383-5p is down-regulated in MM patients, and low expression of miR-383-5p is a risk factor for poor prognosis and can be used as a new prognostic biomarker.
    Journal
    |
    B2M (Beta-2-microglobulin) • MIR383 (MicroRNA 383)
    1year
    The Association Between Anti-Neoplastic Effects of Curcumin and Urogenital Cancers: A Systematic Review. (PubMed, Biomed Res Int)
    Curcumin exerts its anticancer effects on urogenital neoplasms by upregulating tumor suppressor microRNAs (miR-143, miR-145, miR-Let-7, miR-101, miR-3127, miR-3178, miR-1275, miR-3198, miR-1908, miR-770, miR-1247, miR-411, miR-34a, miR-383, miR-708, miR-483, miR-199a, miR-335, miR-503, miR-10b, miR-551a, miR-9, miR-203, miR-7110, miR-29b, and miR-126) and downregulating oncogenic microRNAs (miR-21, miR-210, miR-382, miR-654, miR-494, miR-193b, miR-671, miR-222, miR-23b, miR-664, miR-183, miR-214, miR-320a, miR-23a, miR-30a, miR-320d, miR-1285, miR-32, miR-181a, miR-205, miR-216a, miR-1246, and miR-106b). Cell proliferation is inhibited, and cell apoptosis is induced by curcumin in different urogenital cancers through suppressing oncogenic microRNAs or provoking tumor suppressor microRNAs.
    Review • Journal
    |
    MIR21 (MicroRNA 21) • MIR34A (MicroRNA 34a-5p) • MIR193B (MicroRNA 193b) • MIR1246 (MicroRNA 1246) • MIR126 (MicroRNA 126) • MIR143 (MicroRNA 143) • MIR199A (MicroRNA 199a) • MIR210 (MicroRNA 210) • MIR216A (MicroRNA 216a) • MIR23A (MicroRNA 23a) • MIR23b (MicroRNA 23b) • MIR320A (MicroRNA 320a) • MIR335 (MicroRNA 335) • MIR494 (MicroRNA 494) • MIR503 (MicroRNA 503) • MIR664A (MicroRNA 664a) • MIR106B (MicroRNA 106b) • MIR10B (MicroRNA 10b) • MIR1247 (MicroRNA 1247) • MIR127 (MicroRNA 127) • MIR145 (MicroRNA 145) • MIR181A1 (MicroRNA 181a-1) • MIR183 (MicroRNA 183) • MIR203A (MicroRNA 203a) • MIR205 (MicroRNA 205) • MIR214 (MicroRNA 214) • MIR222 (MicroRNA 222) • MIR30A (MicroRNA 30a) • MIR3178 (MicroRNA 3178) • MIR383 (MicroRNA 383) • MIR483 (MicroRNA 483) • MIR671 (MicroRNA 671) • MIR708 (MicroRNA 708)
    over1year
    Sushi Domain Containing 2 Dysfunction Contributes to Cancer Progression in Patients with Bladder Cancer. (PubMed, J Cancer)
    In addition, miR-383-5p directly targeted the 3'UTR of SUSD2, with its ectopic expression inhibiting the growth and motility of bladder cancer cells. Our study revealed that miR-383-5p/SUSD2 axis dysfunction may contribute to a poor prognosis for bladder cancer by affecting cell growth, metastasis, and the tumor microenvironment.
    Journal
    |
    MIR383 (MicroRNA 383)
    over1year
    hsa_circ_0000129 targets miR-383-5p/tropomyosin 3 axis to facilitate ovarian cancer progression. (PubMed, Biotechnol Appl Biochem)
    Mechanistically, hsa_circ_0000129 has a sponging effect on miR-383-5p, which targets TPM3. Hsa_circ_0000129 stimulated development of the malignant ovarian cancer phenotype by sponging miR-383-5p and releasing TPM3.
    Journal
    |
    TPM3 (Tropomyosin 3) • MIR383 (MicroRNA 383)